3月18日 - ** 诊断产品制造商Biomerica BMRA.O的股价盘前上涨8.2%至2.25美元
** 该公司称其Hp Detect粪便检验在欧洲获得了第一份商业订单，订单来自欧洲最大的连锁实验室之一
** 检测幽门螺杆菌，这是一种常见的胃部细菌，可导致溃疡和胃癌，并且由于抗生素耐药性而难以治疗 -BMRA
** 该订单面向英国市场，是继今年2月获得英国药品监管机构批准后达成的。
** 补充说，连锁实验室的广泛覆盖面有助于扩大在欧洲的销售，并随着检测成为常规而带来重复订单
** 幽门螺杆菌影响欧洲五大国家约 45% 的人口
** 2025 年 BMRA增长约 5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.